Experimental migraine drug shows promise - Ubrogepant
Among those who were given the drug Ubrogepant, nearly 22% were free of migraine pain symptoms two hours later.
That is compared to the 14% who were on the placebo.
An FDA decision on approval is expected next month.
Copyright 2019 NBC News. All rights reserved.
Among those who were given the drug Ubrogepant, nearly 22% were free of migraine pain symptoms two hours later.
That is compared to the 14% who were on the placebo.
An FDA decision on approval is expected next month.
Copyright 2019 NBC News. All rights reserved.